EUVIMEDEUVIMED entdecken
Crossref

Long-term denosumab therapy for osteoporosis and its interruption: expert opinion of the Society for Metabolic Bone Diseases working group within the Czech Medical Association of J.E. Purkyně

Milan Bayer, Pavel Horák, Vladimír Palička, Karel Pavelka, Richard Pikner, Rosa Jan, František Šenk, Václav Vyskočil, Vít Zikán

Clinical Osteology · 2018

DOI: 10.36290/clo.2018.007 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Osteology, 2018. Verfasst von Milan Bayer und 8 weiteren Autor:innen. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 28 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Bayer, M., Horák, P., Palička, V., Pavelka, K., Pikner, R., Jan, R., Šenk, F., Vyskočil, V., & Zikán, V. (2018). Long-term denosumab therapy for osteoporosis and its interruption: expert opinion of the Society for Metabolic Bone Diseases working group within the Czech Medical Association of J.E. Purkyně. Clinical Osteology. https://doi.org/10.36290/clo.2018.007

Vancouver

Bayer M, Horák P, Palička V, Pavelka K, Pikner R, Jan R, et al. Long-term denosumab therapy for osteoporosis and its interruption: expert opinion of the Society for Metabolic Bone Diseases working group within the Czech Medical Association of J.E. Purkyně. Clinical Osteology. 2018. doi:10.36290/clo.2018.007

BibTeX
@article{Bayer2018,
  author = {Bayer, Milan and Horák, Pavel and Palička, Vladimír and Pavelka, Karel and Pikner, Richard and Jan, Rosa and Šenk, František and Vyskočil, Václav and Zikán, Vít},
  title = {Long-term denosumab therapy for osteoporosis and its interruption: expert opinion of the Society for Metabolic Bone Diseases working group within the Czech Medical Association of J.E. Purkyně},
  journal = {Clinical Osteology},
  year = {2018},
  doi = {10.36290/clo.2018.007}
}
Kostenlos starten →